Darifenacin
- TRADE NAMES: Emselex (Novartis); Enablex (Novartis)
- INDICATIONS: Overactive bladder
- CLASS: Anticholinergic, Muscarinic antagonist
- HALF-LIFE: 13–19 hours
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Anticholinergics, Antihistamines, Atazanavir, Clozapine, Cyclosporine, Digoxin, Disopyramide, Domperidone, Erythromycin, Flecainide, Fosamprenavir, Haloperidol, Imipramine, Indinavir, Itraconazole, Ketoconazole, Levodopa, Lopinavir, MAO inhibitors, Memantine, Metoclopramide, Nefopam, Nelfinavir, Nitrates (sublingual), Parasympathomimetics, Paroxetine Hydrochloride, Phenothiazines, Potent CYP3A4 inhibitors, Ritonavir, Saquinavir, Thioridazine, Tipranavir, Tricyclic antidepressants, Verapamil
PREGNANCY CATEGORY: C
Contra-indicated in patients with, or at risk for, urinary retention, gastric retention or uncontrolled narrow-angle glaucoma.
Please login to see the rest of this drug profile
SKIN.
MUCOSAL.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
GASTROINTESTINAL/HEPATIC.
GENITOURINARY.
OCULAR.
RESPIRATORY.
Page last updated 07/31/2023
Symbol key
Incidence
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric